- Home
- IMMR vs ACIU Comparison
IMMR vs ACIU Comparison
Compare IMMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMR
- ACIU
- Stock Information
- Founded
- IMMR 1993
- ACIU 2003
- Country
- IMMR United States
- ACIU Switzerland
- Employees
- IMMR N/A
- ACIU N/A
- Industry
- IMMR Computer peripheral equipment
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- IMMR Technology
- ACIU Health Care
- Exchange
- IMMR Nasdaq
- ACIU Nasdaq
- Market Cap
- IMMR 251.7M
- ACIU 213.3M
- IPO Year
- IMMR 1999
- ACIU 2016
- Fundamental
- Price
- IMMR $7.17
- ACIU $3.53
- Analyst Decision
- IMMR Strong Buy
- ACIU Strong Buy
- Analyst Count
- IMMR 2
- ACIU 2
- Target Price
- IMMR $12.25
- ACIU $10.00
- AVG Volume (30 Days)
- IMMR 463.8K
- ACIU 261.7K
- Earning Date
- IMMR 09-11-2025
- ACIU 11-04-2025
- Dividend Yield
- IMMR 2.50%
- ACIU N/A
- EPS Growth
- IMMR 57.07
- ACIU N/A
- EPS
- IMMR 2.04
- ACIU N/A
- Revenue
- IMMR $163,133,000.00
- ACIU $36,362,036.00
- Revenue This Year
- IMMR $988.71
- ACIU N/A
- Revenue Next Year
- IMMR $109.72
- ACIU $1,022.98
- P/E Ratio
- IMMR $3.48
- ACIU N/A
- Revenue Growth
- IMMR 338.21
- ACIU 86.71
- 52 Week Low
- IMMR $6.47
- ACIU $1.43
- 52 Week High
- IMMR $10.72
- ACIU $3.99
- Technical
- Relative Strength Index (RSI)
- IMMR 46.14
- ACIU 68.67
- Support Level
- IMMR $6.96
- ACIU $2.70
- Resistance Level
- IMMR $7.48
- ACIU $3.99
- Average True Range (ATR)
- IMMR 0.19
- ACIU 0.29
- MACD
- IMMR -0.02
- ACIU 0.09
- Stochastic Oscillator
- IMMR 18.62
- ACIU 80.31
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.